A Closer Look At Johnson & Johnson's Pharmaceuticals Business
When many investors think of Johnson & Johnson , they tend to think of a slow growth company that draws in income investors with its 5-year average dividend yield of 3.3%. Yet shares of J&J have climbed 26% over the past 12 months -- handily outperforming the S&P 500's 16% gain.
J&J has emerged as a major force in all three of its business divisions -- consumer health care, medical devices, and pharmaceuticals -- which all contributed to its 172% jump in earnings and 8.5% revenue growth last quarter. J&J's pharmaceuticals business was its fastest growing division, reporting 11.7% year-over-year sales growth compared to 9.6% and 1.1% growth at its medical devices and consumer health care businesses, respectively.
In addition, its pharmaceuticals segment grew at a faster rate than its comparable peers Merck, Pfizer, and GlaxoSmithKline, as seen in the following chart.
Pharma Segment Qty. Revenue
Percentage of total sales
Sources: Quarterly reports and author's calculations.
Why is J&J's pharmaceuticals business outgrowing its rivals? Let's take a closer look at the key factors.
A closer look at J&J's nine fastest-growing drugs
J&J's pharmaceutical business is as diversified as a mutual fund, but its immunology and neuroscience treatments have the most weight, respectively accounting for 31% and 26% of the division's total sales in 2012.
Here are the nine fastest growing drugs in J&J's portfolio, which together accounted for 58% of the segment's sales last quarter.
Percentage of total pharma sales
rheumatoid/psoriatic arthritis, Crohn's disease
blood clot prevention
Sources: Company report on sales of key franchises, author's calculations.
From this chart, we can see that Remicade, which now nearly accounts for a fourth of the division's revenue, is the backbone of J&J's pharmaceutical sales. J&J has a marketing partnership with Merck to sell Remicade worldwide, but J&J retains the larger portion of global sales.
Two top sellers could face threats
The top concern for J&J investors is the upcoming European patent expiration of Remicade in February 2015.
On Sept. 10, the European Commission approved Hospira and Celltrion's biosimilar version of Remicade, Inflectra. In addition, Hospira's phase 3 study showed that 73.4% of patients on Inflectra showed a 20% or more improvement in rheumatoid arthritis symptoms, compared to a 69.7% improvement rate in patients on Remicade.
Although the eventual market price of Inflectra is unknown, generic biosimilar products are usually sold at lower prices than their branded equivalents. Therefore, Inflectra's higher efficacy rate and a possibly lower price threaten Remicade's future in the European market.
Meanwhile, J&J's prostate cancer treatment Zytiga, which grew sales by 70% last quarter, could become the company's second most important drug. Zytiga has grown at the expense of Dendreon 's Provenge, a cheaper treatment with a lower median extension of a patient's life. Patients on Zytiga showed a median increased survival rate of 4.6 months, compared to 4.1 months for Provenge.
However, both Zytiga and Provenge are threatened by a newer treatment, Medivation and Astellas' Xtandi, which increases the median survival rate by 4.8 months for a cheaper price than both treatments. Zytiga could also face generic competition as early as 2016.
To stave off these two threats, J&J acquired Aragon Pharmaceuticals in June for its pipeline of experimental prostate cancer treatments.
A closer look at the worst performing drugs
Yet J&J also has some major laggards in its drug portfolio. Here are four of the worst performing ones last quarter.
Percentage of total pharma sales
Sources: Company report on sales of key franchises, author's calculations
Two of these -- Risperdal Consta and Concerta -- deserve a closer look.
J&J announced two recalls of Risperdal Consta in June and September, bringing a lot of unwanted attention to its quality control problems, which have also been plaguing its consumer health care division. In June, Risperdal was recalled due to "odor problems" caused by trace amounts of a chemical preservative. In September, more vials were recalled for mold. Those two events definitely won't help turn around Risperdal's fading sales.
Concerta, on the other hand, faces major competition from Shire's Vyvanse, the successor to its best-selling ADHD treatment, Adderall. While Concerta is an sustained release version of Novartis' Ritalin, Vyvanse is a newer treatment that is considered less habit-forming than previous ADHD treatments. Doctors and patients went with the newer treatment, and sales of Vyvanse rose 13% year-over-year to $300 million as Concerta slumped 20% to $215 million.
The Foolish takeaway
J&J's pharmaceuticals business is a rapidly shifting one, but just as a portfolio manager carefully manages rising and falling stocks, J&J has a strong grasp of which drugs to introduce and which ones to phase out.
Generic Remicade remains a major threat to the segment's future growth, but new products -- like Aragon's new prostate cancer treatment and Invokana, a new diabetes treatment that was approved by the FDA in March -- should keep the division growing at a faster clip than J&J's other businesses as well as the pharmaceutical divisions of J&J's primary rivals.
One of the best parts of owning big pharma stocks like J&J is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The article A Closer Look At Johnson & Johnson's Pharmaceuticals Business originally appeared on Fool.com.
Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.